Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function

European Journal of Clinical Investigation

Volumn 28, Issue 6, 1998, Pages 447-452

  Kostner, K M ^a,b   Clodi, M ^a   Bodlaj, G ^a   Watschinger, B ^a   Horl W ^a   Derfler, K ^a   Huber, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b University of Vienna ^*  (Austria)

Author keywords

Plasma Lp(a); Renal function; Urinary apo(a)

Indexed keywords

APOLIPOPROTEIN A; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URINARY EXCRETION;

AGED; APOLIPOPROTEINS A; FEMALE; HUMANS; KIDNEY DISEASES; LIPOPROTEIN(A); MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0031867582     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00319.x     Document Type: Article

References (29)

1. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-bl-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-5.
2. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolobon G. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38: 51-61.
3. Armstrong VW, Cremer P, Eberle E, et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 1986; 62: 249-57.
4. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyana M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
5. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
6. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL-C and other risk factors: results from prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 1994; 24: 444-53.
7. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 300: 132-7.
8. Edelberg JM, Pizzo SV. Lp(a) inhibits plasminogen activation in a template dependent manner. Blood Coagul Fibrinolysis 1991; 2: 759-64.
9. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM. The interaction of lipoprotein Lp(a) and LDL with glycosamino glycans and proteoglycans from human aorta. Arterioscler Thromb 1988; 8: 851-7.
10. Krempler F, Kostner GM, Bolzano K. Turnover of lipoprotein (a) in man. J Clin Invest 1980; 65: 1483-90.
11. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchart JC. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 1987; 33: 721-2.
12. Karadi I, Romics L, Palos G, et al. Lp(a) concentration in serum of patients with heavy proteinuria of different origin. Clin Chem 1989; 35: 2121-3.
13. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J. Elevated Lp(a) levels in primary nephrotic syndrome. Am J Kidney Dis 1993; 22: 808-13.
14. Thomas ME, Freestone A, Varghese Z, Persaud JW, Moorhead JF. Lp(a) in patients with proteinuria. Nephrol Dial Transplant 1992; 7: 597-601.
15. Kronenberg F, König P, Neyer U, et al. Multicenter study of Lp(a) and Apo(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-20.
16. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1-25.
17. Irish AB, Hayes JM, Simons LA, Simons J, Savdie E. Lp(a) levels in chronic renal disease states, dialysis and transplantation. Aust NZ J Med 1992; 22: 243-8.
18. Parsy D, Dracon M, Cachera C, et al. Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 1988; 3: 51-6.
19. Black IW, Wilcken DEL. Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 1992; 38: 353-7.
20. Kronenberg F, König P, Lhotta K, et al. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 1994; 14: 1399-404.
21. Oida K, Takai H, Maeda H, et al. Apolipoprotein (a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992; 38/11: 2244-8.
22. Kostner K, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, Kostner G. Urinary excretion of apo(a) fragments: role in apo(a) catabolism. Atheroscl Thromb Vasc Biol 1996; 16/8: 905-11.
23. Mooser V, Miguel CS, Moeen A, Landschulz K, Marcovina S, Hobbs HH. Apolipoprotein (a) Kringle 4-containing fragments in human urine. J Clin Invest 1996; 97: 858-64.
24. Kostner K, Jansen M, Maurer G, Derfler K. LDL-apheresis significantly reduces urinary apo(a) excretion. Eur J Clin Invest 1997; 27: 93-5.
25. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996; 98: 2414-24.
26. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145-50.
27. Liu R, Saku K, Kostner GM, et al. In vivo kinetics of lipoprotein(a) in homozygous Watanabe heritable hyperlipidemic rabbits. Eur J Clin Invest 1993; 23: 561-5.
28. Sandholzer C, Hallman DM, Saha N, et al. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet 1991; 86: 607-14.
29. Kronenberg F, Trenkwalder E, Lingenhel A, et al. Renovascular arteriovenous differences in Lp(a) plasma concentrations suggest removal of Lp(a) from the renal circulation. J Lipid Res 1997; 38: 1755-63.